Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMK3RL8)

Drug Name

Somatropin intranasal rhGH Drug Info

Synonyms

ALTU-238; CP-024; HGH-191; Somatropin (intranasal); Human growth hormone (crystalline), Altus/Genentech; RhGH (oral, eligen), Novartis; Somatropin (crystalline), Altus/Genentech; Somatropin (sustained release, subcutaneous), Althea; Humatrope (oral, CADDYS), Lilly/Emisphere; Recombinant human growth hormone (oral, CADDYS), Lilly/Emisphere; RhGH (oral, CADDYS), Lilly/Emisphere; RhGH (oral, eligen), Emisphere/Novartis; Somatropin (nasal spray, CriticalSorb, growth hormone deficiency), Critical Pharmaceuticals; Somatropin (oral, CADDYS), Lilly/Emisphere; Somatropin (sustained release, subcutaneous), Altus/Genentech; Human growth hormone, (sustained release, subcutaneous), Altus/Genentech

Indication

Disease Entry	ICD 11	Status	REF
Growth hormone deficiency	5A61.3	Phase 2	[1]

Cross-matching ID

TTD Drug ID: DMK3RL8

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Somatotropin (GH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lonapegsomatropin	DMPR8E9	Growth failure	LD2F.1Y	Approved	[3]
HGH-CTP	DMXAZ47	Growth hormone deficiency	5A61.3	Phase 3	[4]
Albutropin	DMWAL73	Growth failure	LD2F.1Y	Phase 3	[5]
VRS-317	DMWMT5N	Growth hormone deficiency	5A61.3	Phase 3	[6]
YPEG-Somatropin	DMCM0K6	Growth hormone deficiency	5A61.3	Phase 1	[7]
ARX-201	DMS0LCZ	Growth failure	LD2F.1Y	Discontinued in Phase 2	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Somatotropin (GH1)	TTT3YKH	SOMA_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00837863) Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency. U.S. National Institutes of Health.
2	Long-term efficacy and safety of somatropin for adult growth hormone deficiency.Treat Endocrinol.2003;2(2):109-20.
3	ClinicalTrials.gov (NCT01947907) Safety, PK/PD and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD). U.S. National Institutes of Health.
4	Developments in human growth hormone preparations: sustained-release, prolonged half-life, novel injection devices, and alternative delivery routes. Int J Nanomedicine. 2014; 9: 3527-3538.
5	Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur J Pharmacol. 2002 Dec 5;456(1-3):149-58.
6	Company report (Versartis)
7	Somatropin therapy in adults with Prader-Willi syndrome. Treat Endocrinol. 2004;3(3):153-60.
8	Company report (Avarx)